Sandy Spring Bank’s Immunogen Inc IMGN Stock Holding History

Sandy Spring Bank’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-132	Closed	-$1K	–	856
2018 Q1	$1K	Hold	132	–	–	﹤0.01%	827
2017 Q4	$1K	Buy	+132	New	+$814	﹤0.01%	827

Other funds holding IMGN

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sandy Spring Bank's IMGN Position: Q2 2018 in Review

Sandy Spring Bank sold out of Immunogen Inc (IMGN) in Q2 2018, closing a stake of 132 shares — an estimated $1K sold.

Sandy Spring Bank first reported a position in IMGN in Q4 2017 and held it in 2 quarters. The position peaked at $1K in Q1 2018. 198 funds tracked by Wall St. Rank hold IMGN as of Q2 2018.

Sandy Spring Bank reported no remaining Immunogen Inc position as of Q2 2018 after selling out during the quarter.
Sandy Spring Bank sold 132 Immunogen Inc shares in Q2 2018, an estimated $1K.
Sandy Spring Bank first reported a position in Immunogen Inc in Q4 2017 and held it in 2 quarters.
Sandy Spring Bank's Immunogen Inc position peaked at $1K in Q1 2018.
198 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2018.

Based on Sandy Spring Bank's 13F filing for Q2 2018, filed 3 Aug 2018.